PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics
Overview
Authors
Affiliations
The implementation of clinical pharmacogenetics in daily practice is limited for various reasons. Today, however, it is a discipline in full expansion. Accordingly, in the recent times, several initiatives promoted its implementation, mainly in the United States but also in Europe. In this document, the genotyping results since the establishment of our Pharmacogenetics Unit in 2006 are described, as well as the historical implementation process that was carried out since then. Finally, this progress justified the constitution of La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics (PriME-PGx), promoted by the Clinical Pharmacology Department of Hospital Universitario de La Princesa (Madrid, Spain). Here, we present the initiative along with the two first ongoing projects: the PROFILE project, which promotes modernization of pharmacogenetic reporting (i.e., from classic gene-drug pair reporting to complete pharmacogenetic reporting or the creation of pharmacogenetic profiles specific to the Hospital's departments) and the GENOTRIAL project, which promotes the communication of relevant pharmacogenetic findings to any healthy volunteer participating in any bioequivalence clinical trial at the Clinical Trials Unit of Hospital Universitario de La Princesa (UECHUP).
Gonzalez-Iglesias E, Mendez-Ponce C, Ochoa D, Roman M, Mejia-Abril G, Martin-Vilchez S Int J Mol Sci. 2025; 26(1.
PMID: 39796117 PMC: 11720188. DOI: 10.3390/ijms26010260.
Gonzalez-Iglesias E, Ochoa D, Navares-Gomez M, Zubiaur P, Aldama M, de la Torre T Front Pharmacol. 2024; 15:1414059.
PMID: 39484171 PMC: 11524821. DOI: 10.3389/fphar.2024.1414059.
Pharmacogenomics and Big Data in medical oncology: developments and challenges.
Marcu L, Marcu D Ther Adv Med Oncol. 2024; 16:17588359241287658.
PMID: 39483136 PMC: 11526290. DOI: 10.1177/17588359241287658.
Genetic Variation in , , and Alters the Pharmacokinetics and Safety of Mirabegron.
Soria-Chacartegui P, Cendoya-Ramiro P, Gonzalez-Iglesias E, Martin-Vilchez S, Rodriguez-Lopez A, Mejia-Abril G Pharmaceutics. 2024; 16(8).
PMID: 39204422 PMC: 11359404. DOI: 10.3390/pharmaceutics16081077.
Update on the PriME-PGx initiative: evolution of pharmacogenetics in daily clinical practice.
Gonzalez-Iglesias E, Abad-Santos F Pharmacogenomics. 2024; 25(8-9):401-406.
PMID: 39115196 PMC: 11418291. DOI: 10.1080/14622416.2024.2375188.